137 related articles for article (PubMed ID: 10184934)
1. Secondary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S201-8. PubMed ID: 10184934
[No Abstract] [Full Text] [Related]
2. Primary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
[No Abstract] [Full Text] [Related]
3. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
Lim PO; Yee KM
Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
[No Abstract] [Full Text] [Related]
4. Therapy and clinical trials.
Bhatnagar D
Curr Opin Lipidol; 1997 Jun; 8(3):U44-6. PubMed ID: 9211075
[No Abstract] [Full Text] [Related]
5. Primary prevention of coronary artery disease.
Domanski MJ
N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
[No Abstract] [Full Text] [Related]
6. Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Elam MB; Cushman W; Applegate WB; Heimberg M
Tenn Med; 1997 May; 90(5):189-92. PubMed ID: 9130876
[No Abstract] [Full Text] [Related]
7. Pharmacoeconomics perspectives: payers, providers, and patients.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S221-4. PubMed ID: 10184937
[No Abstract] [Full Text] [Related]
8. Cholesterol reduction and coronary prevention.
Prabhakaran D
Natl Med J India; 1997; 10(1):24-5. PubMed ID: 9069704
[No Abstract] [Full Text] [Related]
9. Reduction of coronary events by pravastatin--is lowering low-density lipoprotein cholesterol the answer?
Halle M; Bery A; Keul J
Am J Cardiol; 1997 Sep; 80(5):683. PubMed ID: 9295011
[No Abstract] [Full Text] [Related]
10. Lipid-lowering therapy for average lipid levels: the CARE trial.
Sprecher DL
Cleve Clin J Med; 1997 Mar; 64(3):129-31. PubMed ID: 9068221
[No Abstract] [Full Text] [Related]
11. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
12. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
13. Updated guidelines support even lower cholesterol levels for at-risk patients.
Levenson D
Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
[No Abstract] [Full Text] [Related]
14. The effect of pravastatin on coronary events after myocardial infarction.
Hazzard WR; Ettinger WH
N Engl J Med; 1997 Mar; 336(13):961; author reply 962. PubMed ID: 9072700
[No Abstract] [Full Text] [Related]
15. [CARE[ Cholesterol and Recurrent Events Trial]].
Oida K
Nihon Rinsho; 2001 Mar; 59 Suppl 3():427-32. PubMed ID: 11347108
[No Abstract] [Full Text] [Related]
16. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
17. Lowering cholesterol with drugs and diet.
Pedersen TR
N Engl J Med; 1995 Nov; 333(20):1350-1. PubMed ID: 7566029
[No Abstract] [Full Text] [Related]
18. [Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
Z Kardiol; 1998 Apr; 87(4 Suppl Uberzeugen):1-3. PubMed ID: 9618895
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L
Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184
[TBL] [Abstract][Full Text] [Related]
20. Risk factor modification: rationale for management of dyslipidemia.
Gotto AM
Am J Med; 1998 Feb; 104(2A):6S-8S. PubMed ID: 9550500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
